

Roy Haskell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11953029/publications.pdf>

Version: 2024-02-01

8
papers

424
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

481
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Polymer-Water Interaction and Its Implication for the Dissolution Performance of Amorphous Solid Dispersions. <i>Molecular Pharmaceutics</i> , 2015, 12, 576-589.	4.6	133
2	Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction. <i>Pharmaceutical Research</i> , 2016, 33, 2445-2458.	3.5	92
3	Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion. <i>Molecular Pharmaceutics</i> , 2016, 13, 2787-2795.	4.6	52
4	Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 317-326.	3.3	51
5	Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 568-572.	2.8	45
6	Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4369-4385.	6.4	26
7	Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 <i>R</i> ,3 <i>S</i> ,5 <i>R</i> ,5 <i>b</i> <i>R</i> ,7 <i>a</i> <i>R</i> ,11 <i>a</i> <i>S</i> ,11 <i>b</i> <i>R</i> ,13 <i>a</i> <i>R</i> ,13 <i>b</i> <i>R</i>)-3a-((2-(1,1-Dioxidothiomethyl)ethyl)amino)butyl)benzoic Acid (GSK3532795, BMS-955176). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7289-7313.	6.4	23
8	Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1217-1222.	2.8	2